Abstract:Background: The classification of Parkinson disease by age of onset has proven to be a valuable method for subtyping, given its practical application in clinical settings. However, the interactions between the metabolic brain changes, dopaminergic dysfunction, and clinical manifestations in patients with early-onset (early-iPD) and late-onset (late-iPD) idiopathic Parkinson disease have not been adequately evaluated. Therefore, this study aimed to investigate the difference in cerebral metabolism and presynaptic dopaminergic function between patients with early-iPD and those with late-onset disease using 18F-fluorodeoxyglucose (18F-FDG) and [18F] 9-fluoropropyl-(+)-dihydrotetrabenazine (18F-FP-DTBZ) positron emission tomography (PET). Furthermore, the goal was to further explore the correlation between imaging measurements and clinical manifestations in the early and late idiopathic patients with Parkinson disease. Methods: This cross-sectional study included 80 patients with idiopathic Parkinson disease and 29 healthy control participants who underwent 18F-FDG and18F-FP-DTBZ PET imaging at Xuanwu Hospital, Capital Medical University from August 2022 to August 2023. The patients were categorized into early-iPD (n=27) and late-iPD (n=53) groups based on an age threshold of 50 years. The mean standardized uptake value of 18F-FDG and the standardized uptake value ratio (SUVR) of 18F-FP-DTBZ were compared between the early-iPD and late-iPD groups using unpaired Student t-tests. Furthermore, pairwise correlations among cerebral metabolism, dopaminergic function, and corresponding clinical ratings in all patients were conducted using Pearson correlation analysis. Results: Patients with late-iPD exhibited a significant metabolic decrease in the frontal, parietal, and temporal cortex, along with the globus pallidus, putamen, thalamus, and cerebellum, compared to those with early-iPD in 18F-FDG PET imaging (all P values <0.05). Furthermore, the 18F-FP-DTBZ binding potential was significantly lower in the contralateral caudate and anterior putamen of patients with late-iPD compared to those with early-iPD (contralateral caudate: 3.16±1.2 vs. 2.63±0.7, P=0.020; contralateral anterior putamen: 2.49±1.2 vs. 2.05±0.7, P=0.040). Further analysis of the correlations between imaging clinical features revealed that glucose metabolism increases and dopaminergic function decreases with higher motor ratings. Conclusions: 18F-FDG and 18F-FP-DTBZ PET offer an objective molecular imaging basis for distinguishing between early-onset and late-onset idiopathic with Parkinson disease. Additionally, correlation analysis between imaging and clinical data represents a new approach for exploring the potential applications in future studies involving patients with early-iPD and late-iPD.

Comparison of 18F-DOPA and 18F-DTBZ for PET/CT Imaging of Idiopathic Parkinson’s Disease

Comparison of 18F-DOPA and 18F-DTBZ for PET/CT Imaging of Idiopathic Parkinson Disease

Investigating the Role of 99Mtc-Trodat-1 SPECT Imaging in Idiopathic Parkinson's Disease.

Assessment of Sensitivity for Early Diagnosis of Parkinson’s Disease with ~(18)F-FP-CIT Dopamine Trans porter PET Imaging and ~(99)Tc~m-TRODAT-1 SPECT Imaging

F-18-Fp-Cit Pet Imaging And Spm Analysis Of Dopamine Transporters In Parkinson'S Disease In Various Hoehn & Yahr Stages

18 F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson’s disease in various Hoehn & Yahr stages

Study of dopamine transporter imaging in different stages of Parkinson's disease

The combination of 18F-fluorodeoxyglucose and 18F 9-fluoropropyl-(+)-dihydrotetrabenazine positron emission tomography for distinguishing between early-onset and late-onset idiopathic Parkinson disease and analyzing influencing factors

Clinical Research of [18F]FDG Cerebral Metabolism and [11C]CFT Dopamine Transporter PET Imaging in Parkinson’s Disease

Quantitative Research of 11C-CFT and 18F-FDG PET in Parkinson's Disease: A Pilot Study With NeuroQ Software

The Value of PET/CT in the Diagnosis and Differential Diagnosis of Parkinson’s Disease: a Dual-Tracer Study

Imaging of dopamine transporters in Parkinson disease: a meta‐analysis of 18F/123I‐FP‐CIT studies

Dopamine transporter imaging in the different stages of Parkinson's disease and UPDRS score

Imaging of dopamine transporters in Parkinson disease: a meta-analysis of <SUP>18</SUP>F/<SUP>123</SUP>I-FP-CIT studies

The value of PET/CT in the diagnosis and differential diagnosis of Parkinson's disease: a dual-tracer study

Comparable Investigation in Dopamine Transporters with 99Mtc-Trodat-1 and 131I-FP-CIT SPECT in Parkinson's Disease Patients

Study on ~(99M)tc-Trodat-1 SPECT in Diagnosis of Early Parkinson's Disease

International Consensus on Clinical Use of Presynaptic Dopaminergic Positron Emission Tomography Imaging in Parkinsonism.

[A study of microPET for assessing regional cerebral glucose metabolism and the expression of dopamine receptor type 2 in a rat model of Parkinson's disease].

Application of DAT SPECT for diagnosing and assessing idiopathic parkinson's disease

Study on the ~(99m)Tc-TRODAT-1 DAT SPECT imaging of dopamine transporter in Parkinson's disease